Concepedia

Mark S. Berger

MS

40

Publications

8.9K

Citations

28

H-Index

1978

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Actinium Pharmaceuticals (United States)

University of Pennsylvania

Fred Hutch Cancer Center

GlaxoSmithKline (United States)

Mark S. Berger is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pathology.

Top concepts

Publications per year

1978–2020

40

Publications

40

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.4K citations · Full text

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

Gottfried E. Konecny, Mark D. Pegram, Natarajan Venkatesan et al. · Cancer Research · 2006 · 904 citations

, , +11

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

Eric L. Sievers, Richard A. Larson, Edward A. Stadtmauer et al. · Journal of Clinical Oncology · 2001 · 882 citations

Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.

Mark S. Berger, Gottfried W. Locher, Susanne Saurer et al. · PubMed · 1988 · 570 citations

, , +19

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

Richard A. Larson, Eric L. Sievers, Edward A. Stadtmauer et al. · Cancer · 2005 · 451 citations

Rows per page

1–5 of 40